These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62 related articles for article (PubMed ID: 7659879)
1. [Expression of p29, estrogen receptor related protein in primary breast carcinoma. Methodological, anatomoclinical, and DNA content analysis]. Araya JC; Roa I; Wistuba I; Villaseca MA; Contreras E; Olcese A; Danton A Rev Med Chil; 1994 Oct; 122(10):1140-6. PubMed ID: 7659879 [TBL] [Abstract][Full Text] [Related]
3. Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. Zukerberg LR; Yang WI; Gadd M; Thor AD; Koerner FC; Schmidt EV; Arnold A Mod Pathol; 1995 Jun; 8(5):560-7. PubMed ID: 7675778 [TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of the functional status of estrogen receptor cascade in breast cancer. Kolár Z; Ehrmann J; Dusková M Neoplasma; 1998; 45(2):83-7. PubMed ID: 9687888 [TBL] [Abstract][Full Text] [Related]
5. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors. Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618 [TBL] [Abstract][Full Text] [Related]
6. Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters. Rosanelli GP; Steindorfer P; Wirnsberger GH; Klimpfinger M; Ratschek M; Puerstner P; Auner H; Berhold A Anticancer Res; 1995; 15(2):581-6. PubMed ID: 7763041 [TBL] [Abstract][Full Text] [Related]
7. [Immunohistochemical tumor markers in infiltrating ductal breast carcinoma]. Gallegos M; González S; León A; Claure R; Goñi I; Andrade L; Duarte I Rev Med Chil; 1998 Oct; 126(10):1216-23. PubMed ID: 10030093 [TBL] [Abstract][Full Text] [Related]
8. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma. Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793 [TBL] [Abstract][Full Text] [Related]
9. [Gallbladder cancer: immunohistochemical expression of the protein related to estrogen receptor (p29) and of the protein induced by estrogen (pS2)]. Roa I; Araya JC; Villaseca M; de Artxabala X; Ferreira A; Roa JC Rev Med Chil; 1995 Nov; 123(11):1333-40. PubMed ID: 8733275 [TBL] [Abstract][Full Text] [Related]
10. Downregulation of the potential suppressor gene IGFBP-rP1 in human breast cancer is associated with inactivation of the retinoblastoma protein, cyclin E overexpression and increased proliferation in estrogen receptor negative tumors. Landberg G; Ostlund H; Nielsen NH; Roos G; Emdin S; Burger AM; Seth A Oncogene; 2001 Jun; 20(27):3497-505. PubMed ID: 11429696 [TBL] [Abstract][Full Text] [Related]
11. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523 [TBL] [Abstract][Full Text] [Related]
12. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study. Ottesen GL APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women. Temmim L; Baker H; Sinowatz F Anticancer Res; 2001; 21(1B):743-8. PubMed ID: 11299837 [TBL] [Abstract][Full Text] [Related]
14. Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry. Stål O; Sullivan S; Sun XF; Wingren S; Nordenskjöld B Cytometry; 1994 Jun; 16(2):160-8. PubMed ID: 7924685 [TBL] [Abstract][Full Text] [Related]
15. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Guler G; Uner A; Guler N; Han SY; Iliopoulos D; Hauck WW; McCue P; Huebner K Cancer; 2004 Apr; 100(8):1605-14. PubMed ID: 15073846 [TBL] [Abstract][Full Text] [Related]
16. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression. Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840 [TBL] [Abstract][Full Text] [Related]
17. Comparing the clinical, histopathological and myoepithelial features of estrogen receptor positive and negative mammary carcinomas. Gucin Z; Aksoy B; Gunver F; Pasaoglu E; Bahadir F Saudi Med J; 2006 Apr; 27(4):470-6. PubMed ID: 16598322 [TBL] [Abstract][Full Text] [Related]
18. Estrogen and progesterone receptors and anti-gross cystic disease fluid protein 15 (BRST-2) fail to distinguish metastatic breast carcinoma from eccrine neoplasms. Wallace ML; Longacre TA; Smoller BR Mod Pathol; 1995 Dec; 8(9):897-901. PubMed ID: 8751328 [TBL] [Abstract][Full Text] [Related]
19. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Bhargava V; Kell DL; van de Rijn M; Warnke RA Am J Pathol; 1994 Sep; 145(3):535-40. PubMed ID: 8080038 [TBL] [Abstract][Full Text] [Related]
20. Expression of human telomerase reverse transcriptase gene and protein, and of estrogen and progesterone receptors, in breast tumors: preliminary data from neo-adjuvant chemotherapy. Kammori M; Izumiyama N; Hashimoto M; Nakamura K; Okano T; Kurabayashi R; Naoki H; Honma N; Ogawa T; Kaminishi M; Takubo K Int J Oncol; 2005 Nov; 27(5):1257-63. PubMed ID: 16211220 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]